MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Similar documents
MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Building Quality Metrics. Mark Birse, Deputy Director & Head of Inspectorate

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Good Documentation Practice Session 2

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

Implementation of EU Falsified Medicines Directive

Good Documentation Practices. Documentation Requirements For Regulated Environments

Qualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy

Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Early Access to Medicines Scheme (EAMS)

Overview SFLGDP1. Develop, implement and maintain a quality system to control the distribution of medicinal products

Inspection findings on Health Based Exposure Limits and Cross Contamination. Graeme McKilligan, UK, MHRA.

Feedback from Inspection Programme

Overview SFLGDP1- HP Develop, implement and maintain a quality system to control the distribution of medicinal products

ECMC Annual Network meeting

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager

Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Healthcare Good Distribution Practice (GDP)

Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation

New GDP Guidelines - Implementation

QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Maritime and Coastguard Agency LogMARINE GUIDANCE NOTE

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

Submission of comments on Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use (SANCO/C8/AM/an D(2010) )

Comparability: Regulatory Perspective

Guidelines on Good Distribution Practice of Medicinal Products for Human Use. CF edition

The challenges of software medical device regulation.

Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE

MEDICINES CONTROL COUNCIL

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Chapter 8 Contract Manufacture and Contract Analysis

MINISTRY OF HEALTH ORDINANCE

GMP Track 1 Day 2 Session 1 Vendor Assurance

Quality Risk Management

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

Competence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)

By Christoph Frick and Nicola Spiggelkötter. Creating a Master Plan for Drug Warehousing, Transportation and Distribution

Overview sulla nuova guideline GDP

Guide to Scientific and Regulatory Advice for GXP activities

Review of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices

Outsourcing - managing risks and opportunities over which you now have less control

MINISTRY OF HEALTH ORDINANCE

Management System Hilton Olympia, London 13 th February 2013

Background to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016

Case Study: how reports of falsified medicinal products can impact wholesale distributors

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

Guide to Good Distribution Practice of Medicinal Products for Human Use

Practical implementation of the Falsified Medicines Directive

DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

The interface between Good Clinical Practice and Good Manufacturing Practice

GIRP-IPF Study 2016 KEY FINDINGS EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION GROUPEMENT INTERNATIONAL DE LA RÉPARTITION PHARMACEUTIQUE

Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers

An analysis of quality product defects in the centralised procedure

Good Distribution Practices Toolkit. Quality Management System 08 March 2016

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

The APIC Audit Programme Version 5, July 2017

Controlled Document Number: Version Number: 2 Controlled Document Sponsor: Controlled Document Lead:

Good Distribution Practice and Supply Chain Risk Evaluation

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013.

GDP Audits : Weak points when conducting GDP Audit based on inspections

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD)

Document Title: Handling of drug alerts and recalls of IMPs

Blackbox for sensitive freight.

Pharmacovigilance Inspection Metrics Report

MEDICINES CONTROL COUNCIL

Section 3 Company Organisation and Certification Procedures

Guidelines relating to good distribution practice for distributors of medical devices.

Logistic Provider Qualification: prerequisites and SLA

ENVIRONMENT AND SUSTAINABLE RESOURCE DEVELOPMENT GRANT REGULATION

SAFE FOOD FOR CANADIANS ACTION PLAN. Strengthening Canada s World-Class Food Safety System

MEDICINES CONTROL COUNCIL

Process and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager

GUIDANCE NOTE 37 MEDICAL GASES DATA INTEGRITY

Inside EU FMD and the Delegated Acts A Compliance Primer

REVISED COMPILATION OF COMMUNITY PROCEDURES ON ADMINISTRATIVE COLLABORATION AND HARMONISATION OF INSPECTIONS

The FIN-FSA s thematic evaluation of the organisation of the compliance function in supervised entities

What to expect from MDR Authorised representatives? Sandra Ferretti Chief Compliance Officer & Public Affairs Director

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products

Specialist Tax Services GUIDE TO CUSTOMS SERVICES

Pharmacovigilance Post July 2012 The new frontier

Orange and Yellow Guides

FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE

AMF Position Compliance function requirements

EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update

Blackbox for sensitive freight.

Guideline for EMVO and NMVO stakeholders: recommendations for alert handling and prevention process. January 2019

Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland

Current Regulatory Developments REG800. 1

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Transcription:

MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015

Complex Business Models - Outsourced Activities Presented by: Jacqueline Masayi, GDP Inspector

Background Increased complexities of the supply chain Virtual Operators Falsified Medicines Directive requiring greater traceability Safe and secure supply chain Legal obligation to ensure licensing requirements are met Regulatory obligation to comply with requirements of GDP 3

Legal Obligation Human Medicines Regulations 2012, Reg. 18 Distribution of a medicinal product by way of wholesale dealing, or possession for the purpose of such distribution.. HMR 2012 distributing = a) selling or supplying b) procuring or holding or exporting Licensing requirement 4

Regulatory Obligation Any GDP activity that is outsourced should be correctly defined, agreed, controlled and there must be a written contract between the contract giver and contract a acceptor which clearly establishes the duties of each party EU Guidelines on GDP, Chapter 7 Outsourced Activities The quality system should extend to the control and review of any outsourced activity EU Guideline on GDP 1.3 Management of Outsourced Activities 5

Examples of contracting in the GDP environment Virtual Operators e.g. MAHs, Mainliners, Shortliners, Small to Medium wholesalers Specials Manufacturers (contract man.) Procurement Logistics providers Storage and Transport Contract RPs Regulatory services Pharmacy Groups IT services Hospitals NHS & Private Freight forwarders/exporters Temperature Mapping 8

Any UK site performing any of the following activities on behalf of the licence holder must be specified on the WDA(H) Procurement Holding: - sites holding ambient products in excess of 36 hours must be licensed. - sites where refrigerated products are held, even when this is for less than 36 hours, must be licensed. Supply Export Is contract Acceptor appropriately licensed to perform the outsourced activity on my behalf? 9

Written Contracts For any activity covered by the GDP Guide that is outsourced: There must be a written contract between the contract giver and contract acceptor which clearly establishes the duties of each party Key elements of a written contract Correctly defined Suitable v generic Clear, unambiguous language, free from errors Subject to regular review Quality and integrity of medicinal products maintained throughout the supply chain Agreed & signed by both parties 10

Written Contracts (sample) 11

Written Contracts (sample) 12

Written Contracts (sample) 13

What could go wrong? Case Study 1 No contract in place No evaluation prior to activity Location from which wholesale activities were performed was not licensed Misunderstandings e.g. Temperature deviation: no communication process, no investigations and no action plan - Quality of products compromised - Recall - Regulatory action taken - Reputational damage 14

Case Study 2 Contract not correct and suitable Named RP was acting for storage and distribution site only The procurement activity was overlooked - Medicines were purchased from a company that did not hold the appropriate authorisation - Legal action - Regulatory action 15

Case Study 3 Contract Giver or Contract Acceptor? Activities and responsibilities not correctly defined Outsourced activities were not adequately controlled Duties of each party not clearly established All activities not covered in the written contract Work passed to third party of contract acceptor without knowledge of contract giver Major deficiency Frequent inspections Risk profile affected 16

Risk Mitigation Strategies Is the company authorised to perform the activity? Check authorisation status ( authorised wholesale operations, site details) Due diligence check EUDRA non compliance statements Is there a Written Contract in place? Regular review and communication of any changes appropriately to all Contract Givers. 17

Risk Mitigation Strategies cont. Are outsourced activities controlled and reviewed within quality system? - Suitability and competence of contract acceptor assessed prior to activity being carried out? - Frequent audits based on risk - Responsibilities and communication processes defined - Performance monitoring and review to identify and implement required improvements on a regular basis 18

Risk Mitigation Strategies cont. The written contract should require the Contract Acceptor to forward any information that can influence the quality of the products to the Contract Giver e.g. Temperature deviation during transportation should be reported to the wholesale distributor and recipient of the affected products Changes premises, key personnel Work entrusted to the Contract Acceptor should not be passed to a 3rd party without prior approval and evaluation by the Contract Giver. 19

Why is this important? Compliance Legal and Regulatory Patient Safety Maintaining the quality and integrity of products Proper distribution of medicinal products; procured, held, supplied and exported in a way that is compliant with GDP) Business Cost effective Expertise in area Reputation Customers 20

Final thought Outsourcing of GDP activities is becoming increasingly complex Contract Giver Responsible for the activities contracted out. The quality system should extend to control and review of any outsourced activities Contract Acceptor Licensing and GDP requirements apply to outsourced activities Work ordered by Contract Giver must be carried out in accordance with the specific product requirements 21

THANK YOU! 22

Crown copyright 2015 About copyright All material created by the MHRA, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty s Stationery Office (HMSO). The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA. Further information, including an application form for requests to reproduce our material can be found at www.mhra.gov.uk/crowncopyright Material from other organisations The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned. 23